Integrated Biopharma Stock Price Prediction
| INBP Stock | USD 0.34 0.02 5.56% |
Momentum 56
Buy Extended
Oversold | Overbought |
Using Integrated Biopharma hype-based prediction, you can estimate the value of Integrated Biopharma from the perspective of Integrated Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Integrated Biopharma. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Integrated Biopharma to buy its otc stock at a price that has no basis in reality. In that case, they are not buying Integrated because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell otc stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Integrated Biopharma after-hype prediction price | USD 0.34 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as otc price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Integrated |
Integrated Biopharma After-Hype Price Density Analysis
As far as predicting the price of Integrated Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Integrated Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of OTC Stock prices, such as prices of Integrated Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Integrated Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Integrated Biopharma's otc stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Integrated Biopharma's historical news coverage. Integrated Biopharma's after-hype downside and upside margins for the prediction period are 0.02 and 4.85, respectively. We have considered Integrated Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Integrated Biopharma is out of control at this time. Analysis and calculation of next after-hype price of Integrated Biopharma is based on 3 months time horizon.
Integrated Biopharma OTC Stock Price Outlook Analysis
Have you ever been surprised when a price of a OTC Stock such as Integrated Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Integrated Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the OTC price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Integrated Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.31 | 4.51 | 0.09 | 0.02 | 10 Events / Month | 2 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.34 | 0.34 | 0.00 |
|
Integrated Biopharma Hype Timeline
Integrated Biopharma is currently traded for 0.34. The entity has historical hype elasticity of -0.09, and average elasticity to hype of competition of -0.02. Integrated is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at 0.31%. %. The volatility of related hype on Integrated Biopharma is about 7014.0%, with the expected price after the next announcement by competition of 0.32. About 69.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.56. Some equities with similar Price to Book (P/B) outperform the market in the long run. Integrated Biopharma had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in about 10 days. Check out Integrated Biopharma Basic Forecasting Models to cross-verify your projections.Integrated Biopharma Related Hype Analysis
Having access to credible news sources related to Integrated Biopharma's direct competition is more important than ever and may enhance your ability to predict Integrated Biopharma's future price movements. Getting to know how Integrated Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Integrated Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| LNLHF | LeanLife Health | 0.08 | 2 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| HNFSA | Hanover Foods | 0.08 | 2 per month | 0.00 | 0.08 | 0.59 | 0.00 | 15.56 | |
| INDFY | Indofood Agri Resources | 0.00 | 0 per month | 0.00 | 0.09 | 0.00 | 0.00 | 18.39 | |
| NGTF | NightFood Holdings | (0.07) | 8 per month | 0.00 | (0.05) | 19.40 | (16.67) | 64.23 | |
| NPRFF | Nepra Foods | (0.08) | 6 per month | 9.86 | 0.03 | 23.61 | (20.09) | 71.45 | |
| HIGR | Hi Great Group Holding | 0.00 | 0 per month | 20.98 | 0.19 | 98.02 | (73.87) | 531.82 | |
| BABB | BAB Inc | 0.00 | 0 per month | 2.64 | (0.01) | 4.88 | (5.15) | 19.09 | |
| IRCKF | Inter Rock Minerals | (0.59) | 4 per month | 0.00 | 0.07 | 0.00 | 0.00 | 59.33 | |
| EWLU | Merion Inc | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Integrated Biopharma Additional Predictive Modules
Most predictive techniques to examine Integrated price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Integrated using various technical indicators. When you analyze Integrated charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Integrated Biopharma Predictive Indicators
The successful prediction of Integrated Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Integrated Biopharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Integrated Biopharma based on analysis of Integrated Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Integrated Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Integrated Biopharma's related companies.
Pair Trading with Integrated Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Integrated Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Integrated Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Integrated OTC Stock
Moving against Integrated OTC Stock
| 0.74 | HPQ | HP Inc | PairCorr |
| 0.58 | NDEKY | Nitto Denko Corp | PairCorr |
| 0.51 | T | ATT Inc Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Integrated Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Integrated Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Integrated Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Integrated Biopharma to buy it.
The correlation of Integrated Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Integrated Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Integrated Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Integrated Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Integrated OTC Stock Analysis
When running Integrated Biopharma's price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.